FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Kennedy

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Leisha A Emens; M John Kennedy; John H Fetting; Nancy E Davidson; Elizabeth Garrett-Mayer; Deborah K Armstrong
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer.
Elisabeth Iljas Heath; Seamus O'Reilly; R Humphrey; P Sundaresan; Ross C Donehower; SE Sartorius; M John Kennedy; Deborah K Armstrong; Michael A Carducci; J M Sorensen; K Kumor; S Kennedy; Louise B. Grochow
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors.
Hillary A Hahm; Deborah K Armstrong; Tian Ling Chen; Louise B. Grochow; J Passos-Coelho; Steven Goodman; Nancy E Davidson; M John Kennedy
Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Kennedy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2002: Leisha A Emens; M John Kennedy; John H Fetting; Nancy E Davidson; Elizabeth Garrett-Mayer; Deborah K Armstrong
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer.
Breast cancer research and treatment 2002;76(2):145-56.
2001: Elisabeth Iljas Heath; Seamus O'Reilly; R Humphrey; P Sundaresan; Ross C Donehower; SE Sartorius; M John Kennedy; Deborah K Armstrong; Michael A Carducci; J M Sorensen; K Kumor; S Kennedy; Louise B. Grochow
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2001;48(4):269-74.
2000: Hillary A Hahm; Deborah K Armstrong; Tian Ling Chen; Louise B. Grochow; J Passos-Coelho; Steven Goodman; Nancy E Davidson; M John Kennedy
Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2000;6(3A):335-43.
1999: Bahar Mikhak; Marianna Zahurak; MD Abeloff; John H Fetting; Nancy E Davidson; Ross C Donehower; W Waterfield; M John Kennedy
Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Cancer 1999;85(4):899-904.
1999: S Subramanyan; MD Abeloff; S E Bond; Nancy E Davidson; John H Fetting; G B Gordon; M John Kennedy
A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.
Cancer chemotherapy and pharmacology 1999;43(6):497-502.
1998: M John Kennedy; Marianna Zahurak; Ross C Donehower; Dennis A Noe; Louise B. Grochow; SE Sartorius; Tian Ling Chen; Kathy Bowling; M Duerr; Eric K Rowinsky
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):349-56.
1997: Tian Ling Chen; M John Kennedy; L W Anderson; S B Kiraly; K C Black; O M Colvin; Louise B. Grochow
Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(5):544-51.